339 related articles for article (PubMed ID: 27307526)
1. Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial.
Kaeley GS; Evangelisto AM; Nishio MJ; Goss SL; Liu S; Kalabic J; Kupper H
J Rheumatol; 2016 Aug; 43(8):1480-9. PubMed ID: 27307526
[TBL] [Abstract][Full Text] [Related]
2. Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate.
Kaeley GS; Nishio MJ; Goyal JR; MacCarter DK; Wells AF; Chen S; Kupper H; Kalabic J
Arthritis Rheumatol; 2016 Nov; 68(11):2584-2592. PubMed ID: 27214046
[TBL] [Abstract][Full Text] [Related]
3. Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate.
Kaeley GS; MacCarter DK; Pangan AL; Wang X; Kalabic J; Ranganath VK
J Rheumatol; 2018 Dec; 45(12):1628-1635. PubMed ID: 30173153
[TBL] [Abstract][Full Text] [Related]
4. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR
Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.
Goss SL; Klein CE; Jin Z; Locke CS; Rodila RC; Kupper H; Burmester GR; Awni WM
Clin Ther; 2018 Feb; 40(2):309-319. PubMed ID: 29402521
[TBL] [Abstract][Full Text] [Related]
6. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
[TBL] [Abstract][Full Text] [Related]
7. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
Keystone EC; Haraoui B; Guérette B; Mozaffarian N; Liu S; Kavanaugh A
J Rheumatol; 2014 Feb; 41(2):235-43. PubMed ID: 24293583
[TBL] [Abstract][Full Text] [Related]
8. Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients.
Kimura N; Suzuki K; Takeuchi T
Mod Rheumatol; 2016 Sep; 26(5):676-80. PubMed ID: 26708943
[TBL] [Abstract][Full Text] [Related]
9. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.
Edwards CJ; Östör AJK; Naisbett-Groet B; Kiely P
Rheumatology (Oxford); 2018 Jan; 57(1):84-91. PubMed ID: 29155973
[TBL] [Abstract][Full Text] [Related]
10. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.
van der Heijde D; Breedveld FC; Kavanaugh A; Keystone EC; Landewé R; Patra K; Pangan AL
J Rheumatol; 2010 Nov; 37(11):2237-46. PubMed ID: 20889601
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.
Takeuchi T; Yamanaka H; Ishiguro N; Miyasaka N; Mukai M; Matsubara T; Uchida S; Akama H; Kupper H; Arora V; Tanaka Y
Ann Rheum Dis; 2014 Mar; 73(3):536-43. PubMed ID: 23316080
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan.
Tanaka Y; Mimori T; Yamanaka H; Sunaga N; Morita K; Kimura J; Takeuchi T
Mod Rheumatol; 2020 May; 30(3):424-433. PubMed ID: 31267801
[No Abstract] [Full Text] [Related]
13. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
[TBL] [Abstract][Full Text] [Related]
14. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial.
Burmester GR; Kivitz AJ; Kupper H; Arulmani U; Florentinus S; Goss SL; Rathmann SS; Fleischmann RM
Ann Rheum Dis; 2015 Jun; 74(6):1037-44. PubMed ID: 24550168
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis.
Dhir V; Singla M; Gupta N; Goyal P; Sagar V; Sharma A; Khanna S; Singh S
Clin Ther; 2014 Jul; 36(7):1005-15. PubMed ID: 24976447
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.
Chen DY; Chou SJ; Hsieh TY; Chen YH; Chen HH; Hsieh CW; Lan JL
J Formos Med Assoc; 2009 Apr; 108(4):310-9. PubMed ID: 19369178
[TBL] [Abstract][Full Text] [Related]
18. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.
Keystone EC; van der Heijde D; Kavanaugh A; Kupper H; Liu S; Guérette B; Mozaffarian N
J Rheumatol; 2013 Sep; 40(9):1487-97. PubMed ID: 23818718
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
Wiland P; Dudler J; Veale D; Tahir H; Pedersen R; Bukowski J; Vlahos B; Williams T; Gaylord S; Kotak S
J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
[TBL] [Abstract][Full Text] [Related]
20. Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study.
Huffstutter JE; Kafka S; Brent LH; Matucci-Cerinic M; Tang KL; Chevrier M; Sprabery T; DeHoratius RJ
Curr Med Res Opin; 2017 Apr; 33(4):657-666. PubMed ID: 28035867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
